Published in J Immunol on August 01, 2011
Matricellular proteins in cardiac adaptation and disease. Physiol Rev (2012) 2.01
Wasting mechanisms in muscular dystrophy. Int J Biochem Cell Biol (2013) 1.07
Age dependent increase in the levels of osteopontin inhibits skeletal muscle regeneration. Aging (Albany NY) (2012) 0.99
Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy. J Cell Biol (2014) 0.92
Matrix metalloproteinase-9 inhibition improves proliferation and engraftment of myogenic cells in dystrophic muscle of mdx mice. PLoS One (2013) 0.90
Cardiomyopathy in the dystrophin/utrophin-deficient mouse model of severe muscular dystrophy is characterized by dysregulation of matrix metalloproteinases. Neuromuscul Disord (2012) 0.87
Initial pulmonary respiration causes massive diaphragm damage and hyper-CKemia in Duchenne muscular dystrophy dog. Sci Rep (2013) 0.83
Selective Expression of Osteopontin in ALS-resistant Motor Neurons is a Critical Determinant of Late Phase Neurodegeneration Mediated by Matrix Metalloproteinase-9. Sci Rep (2016) 0.80
Featured article: induction of heme oxygenase with hemin improves pericardial adipocyte morphology and function in obese Zucker rats by enhancing proteins of regeneration. Exp Biol Med (Maywood) (2014) 0.78
Osteopontin is expressed in the mouse uterus during early pregnancy and promotes mouse blastocyst attachment and invasion in vitro. PLoS One (2014) 0.78
Deletion of Galgt2 (B4Galnt2) Reduces Muscle Growth in Response to Acute Injury and Increases Muscle Inflammation and Pathology in Dystrophin-Deficient Mice. Am J Pathol (2015) 0.76
Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy. Front Cell Dev Biol (2014) 0.76
Particularly interesting Cys-His-rich protein is highly expressed in human intracranial aneurysms and resists aneurysmal rupture. Exp Ther Med (2016) 0.75
Protective effect of tanshinone IIA against cardiac hypertrophy in spontaneously hypertensive rats through inhibiting the Cys-C/Wnt signaling pathway. Oncotarget (2016) 0.75
Dysregulated mechanisms underlying Duchenne muscular dystrophy from co-expression network preservation analysis. BMC Res Notes (2015) 0.75
Osteopontin stimulates matrix metalloproteinase expression through the nuclear factor-κB signaling pathway in rat temporomandibular joint and condylar chondrocytes. Am J Transl Res (2017) 0.75
Matrix metalloproteinases. J Biol Chem (1999) 12.08
Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol (2007) 10.17
Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev (2000) 8.24
The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science (1989) 6.80
The muscular dystrophies. Lancet (2002) 6.41
Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev (2000) 5.33
Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol (2001) 4.99
Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest (2000) 4.79
Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol (2004) 4.16
Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov (2007) 3.36
Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J Cell Biol (1997) 3.32
Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol (2007) 3.19
Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev (2008) 3.06
Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest (2007) 2.99
Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul Disord (2004) 2.34
Pharmacological strategies for muscular dystrophy. Nat Rev Drug Discov (2003) 2.32
The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol (1990) 2.29
The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res (2004) 2.29
Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci U S A (2005) 2.19
The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis. Hum Pathol (1976) 2.18
Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. FASEB J (2003) 2.12
Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest (2009) 2.10
Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle. Clin Immunol (2001) 1.94
The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve (2001) 1.79
MMPs as therapeutic targets--still a viable option? Semin Cell Dev Biol (2007) 1.78
Matrix metalloproteinases as valid clinical targets. Curr Pharm Des (2007) 1.76
Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation (1998) 1.68
Regulation of cardiomyocyte proliferation and myocardial growth during development by FOXO transcription factors. Circ Res (2008) 1.67
Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity. J Clin Invest (1997) 1.61
Dystrophies and heart disease. Curr Opin Cardiol (1997) 1.58
Expression of matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: a study in experimentally injured and mdx muscles. Dev Biol (1999) 1.58
An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene (2007) 1.57
Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J Biol Chem (2004) 1.56
Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. Hum Mol Genet (2005) 1.53
Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers. FASEB J (2004) 1.50
Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. Hum Mol Genet (2009) 1.44
Do immune cells promote the pathology of dystrophin-deficient myopathies? Neuromuscul Disord (2001) 1.43
Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology (1999) 1.42
Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol (1997) 1.40
Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy. J Mol Cell Cardiol (1999) 1.38
MMP-9 and -12 cause N-cadherin shedding and thereby beta-catenin signalling and vascular smooth muscle cell proliferation. Cardiovasc Res (2008) 1.32
The new frontier in muscular dystrophy research: booster genes. FASEB J (2003) 1.29
Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J Mol Cell Cardiol (1996) 1.27
L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers. Am J Pathol (2008) 1.25
Regulation of phosphatidylinositol 3-kinase (PI3K)/Akt and nuclear factor-kappa B signaling pathways in dystrophin-deficient skeletal muscle in response to mechanical stretch. J Cell Physiol (2006) 1.24
A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol (2011) 1.23
Progression of dystrophic features and activation of mitogen-activated protein kinases and calcineurin by physical exercise, in hearts of mdx mice. FEBS Lett (2002) 1.20
Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis. Curr Opin Rheumatol (2005) 1.18
Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J Cell Physiol (2009) 1.16
Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. Circulation (1998) 1.14
Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential. J Natl Cancer Inst (1985) 1.14
TNF-like weak inducer of apoptosis (TWEAK) activates proinflammatory signaling pathways and gene expression through the activation of TGF-beta-activated kinase 1. J Immunol (2009) 1.14
Major basic protein-1 promotes fibrosis of dystrophic muscle and attenuates the cellular immune response in muscular dystrophy. Hum Mol Genet (2008) 1.11
Activation of JNK1 contributes to dystrophic muscle pathogenesis. Curr Biol (2001) 1.11
Heart involvement in muscular dystrophies due to sarcoglycan gene mutations. Muscle Nerve (1999) 1.08
Dystrophin- and MLP-deficient mouse hearts: marked differences in morphology and function, but similar accumulation of cytoskeletal proteins. FASEB J (2004) 1.07
Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit. Life Sci (2001) 1.06
Increased amounts of collagenase and gelatinase in porcine myocardium following ischemia and reperfusion. J Mol Cell Cardiol (1998) 1.04
Etiologies of cardiomyopathy and heart failure. Nat Med (1999) 1.02
Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice. Am J Pathol (2010) 1.02
Osteopontin in cardiovascular disease: a potential therapeutic target. Cardiol Rev (2010) 0.99
Matrix metalloproteinases MMP-2 and MMP-9 in denervated muscle and injured nerve. Neuropathol Appl Neurobiol (1998) 0.98
Effects of T-lymphocyte depletion on muscle fibrosis in the mdx mouse. Am J Pathol (2005) 0.96
Modulation of type-IV collagenase activity and invasive behavior of metastatic human melanoma (A2058) cells in vitro by monoclonal antibodies to type-IV collagenase. Int J Cancer (1990) 0.95
Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces angiogenesis resulting in impaired growth of regenerated muscle fibers. Hum Mol Genet (2011) 0.93
A look between the cardiomyocytes: the extracellular matrix in heart failure. Mayo Clin Proc (2006) 0.92
Matrix metalloproteinases and collagen ultrastructure in moderate myocardial ischemia and reperfusion in vivo. Am J Physiol Heart Circ Physiol (2000) 0.91
Therapeutic targeting of signaling pathways in muscular dystrophy. J Mol Med (Berl) (2009) 0.90
Attenuation of beta2-adrenergic receptors and homocysteine metabolic enzymes cause diabetic cardiomyopathy. Biochem Biophys Res Commun (2010) 0.89
Activation of calcineurin and stress activated protein kinase/p38-mitogen activated protein kinase in hearts of utrophin-dystrophin knockout mice. Neuromuscul Disord (2001) 0.86
Heart transplantation in patients with inherited myopathies associated with end-stage cardiomyopathy: molecular and biochemical defects on cardiac and skeletal muscle. Transplant Proc (2001) 0.85
Dystrophinopathy, the expanding phenotype. Dystrophin abnormalities in X-linked dilated cardiomyopathy. Circulation (1997) 0.84
Folic acid mitigated cardiac dysfunction by normalizing the levels of tissue inhibitor of metalloproteinase and homocysteine-metabolizing enzymes postmyocardial infarction in mice. Am J Physiol Heart Circ Physiol (2010) 0.82
Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications. Drugs (2001) 0.80
Cytoskeletal defects in cardiomyopathy. J Mol Cell Cardiol (2003) 0.80
Serum matrix metalloproteinase-3 as a novel marker for risk stratification of patients with nonischemic dilated cardiomyopathy. J Card Fail (2007) 0.78
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Spatial clustering of hemorrhages in probable cerebral amyloid angiopathy. Ann Neurol (2005) 2.85
New vision for Revised National Tuberculosis Control Programme (RNTCP): Universal access - "reaching the un-reached". Indian J Med Res (2012) 2.83
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood (2007) 2.76
Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J Cell Biol (2010) 2.47
Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. Mol Ther (2005) 2.27
Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (Lond) (2004) 2.13
Investigation of optimizing and translating pH-sensitive pulsed-chemical exchange saturation transfer (CEST) imaging to a 3T clinical scanner. Magn Reson Med (2008) 2.01
Morphological changes in bile ducts following preoperative biliary stenting. Indian J Gastroenterol (2003) 1.94
Molecular mechanisms of ultraviolet radiation-induced DNA damage and repair. J Nucleic Acids (2010) 1.91
Nuclear factor-kappa B signaling in skeletal muscle atrophy. J Mol Med (Berl) (2008) 1.86
Synthesis, anti-inflammatory, analgesic and kinase (CDK-1, CDK-5 and GSK-3) inhibition activity evaluation of benzimidazole/benzoxazole derivatives and some Schiff's bases. Bioorg Med Chem (2006) 1.81
Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy. Neuron (2012) 1.78
Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. Am J Physiol Lung Cell Mol Physiol (2002) 1.76
Low-level laser therapy: a useful technique for enhancing the proliferation of various cultured cells. Lasers Med Sci (2011) 1.76
Extrahepatic portal venous obstruction and obstructive jaundice: approach to management. J Gastroenterol Hepatol (2005) 1.73
Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats. J Hypertens (2003) 1.71
AAV-mediated gene therapy for retinal degeneration in the rd10 mouse containing a recessive PDEbeta mutation. Invest Ophthalmol Vis Sci (2008) 1.68
A prospective, partially randomized study of pregnancy outcomes and hematologic responses to oral and intramuscular iron treatment in moderately anemic pregnant women. Am J Clin Nutr (2004) 1.68
Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol (2005) 1.68
MicroRNAs as a therapeutic target for cardiovascular diseases. J Cell Mol Med (2009) 1.67
The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets (2009) 1.64
Probiotic Lactobacillus rhamnosus GG and Aloe vera gel improve lipid profiles in hypercholesterolemic rats. Nutrition (2013) 1.61
The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J Cell Biol (2010) 1.61
TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J (2007) 1.60
Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. J Biol Chem (2004) 1.59
Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol (2005) 1.59
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-kappaB and degradation of MyoD protein. J Biol Chem (2006) 1.55
Folic acid improves acetylcholine-induced vasoconstriction of coronary vessels isolated from hyperhomocysteinemic mice: an implication to coronary vasospasm. J Cell Physiol (2011) 1.54
Wound-induced ATP release and EGF receptor activation in epithelial cells. J Cell Sci (2007) 1.54
Pioglitazone prevents cardiac remodeling in high-fat, high-calorie-induced Type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol (2006) 1.50
Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol (2010) 1.50
Intimal redox stress: accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy. Cardiovasc Diabetol (2002) 1.46
Synthesis and antimicrobial evaluation of new chalcones containing piperazine or 2,5-dichlorothiophene moiety. Bioorg Med Chem Lett (2007) 1.46
Alpha 1 antitrypsin deficiency in children with chronic liver disease in North India. Indian Pediatr (2009) 1.44
Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. Hum Mol Genet (2009) 1.44
Usefulness of anti -CCP antibodies in rheumatic diseases in Indian patients. Indian J Med Sci (2009) 1.43
Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure. Am J Physiol Renal Physiol (2009) 1.43
Folic acid improves inner ear vascularization in hyperhomocysteinemic mice. Hear Res (2011) 1.42
Modified needle drainage. A safe and efficient technique of subretinal fluid drainage in scleral buckling procedure. Indian J Ophthalmol (2004) 1.42
Characterization and quantitative determination of impurities in piperaquine phosphate by HPLC and LC/MS/MS. J Pharm Biomed Anal (2006) 1.38
Homocysteine causes cerebrovascular leakage in mice. Am J Physiol Heart Circ Physiol (2005) 1.35
Tuberculosis management practices by private practitioners in Andhra Pradesh, India. PLoS One (2013) 1.33
Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice. J Exp Med (2007) 1.32
H2S protects against methionine-induced oxidative stress in brain endothelial cells. Antioxid Redox Signal (2009) 1.30
Soft tissue cysticercosis - Ultrasonographic spectrum of the disease. Indian J Radiol Imaging (2011) 1.29
Dlk1 is necessary for proper skeletal muscle development and regeneration. PLoS One (2010) 1.28
Mitochondrial division/mitophagy inhibitor (Mdivi) ameliorates pressure overload induced heart failure. PLoS One (2012) 1.28
Hydrogen sulfide mitigates cardiac remodeling during myocardial infarction via improvement of angiogenesis. Int J Biol Sci (2012) 1.27
Skin tissue engineering for tissue repair and regeneration. Tissue Eng Part B Rev (2008) 1.27
Herpes simplex virus 1 infection induces the expression of proinflammatory cytokines, interferons and TLR7 in human corneal epithelial cells. Immunology (2006) 1.24
Intracellular redox state alters NMDA receptor response during aging through Ca2+/calmodulin-dependent protein kinase II. J Neurosci (2010) 1.24
Surgical management of corrosive strictures of stomach. Indian J Gastroenterol (2004) 1.24
Regulation of phosphatidylinositol 3-kinase (PI3K)/Akt and nuclear factor-kappa B signaling pathways in dystrophin-deficient skeletal muscle in response to mechanical stretch. J Cell Physiol (2006) 1.24
Interaction of age and chronic estradiol replacement on memory and markers of brain aging. Neurobiol Aging (2003) 1.23
H2S ameliorates oxidative and proteolytic stresses and protects the heart against adverse remodeling in chronic heart failure. Am J Physiol Heart Circ Physiol (2009) 1.23
Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathog (2010) 1.22
Regulation of homocysteine-induced MMP-9 by ERK1/2 pathway. Am J Physiol Cell Physiol (2005) 1.22
Genomic profiling of messenger RNAs and microRNAs reveals potential mechanisms of TWEAK-induced skeletal muscle wasting in mice. PLoS One (2010) 1.22
Cystathionine-beta-synthase gene transfer and 3-deazaadenosine ameliorate inflammatory response in endothelial cells. Am J Physiol Cell Physiol (2007) 1.22
Contribution of medical colleges to tuberculosis control in India under the Revised National Tuberculosis Control Programme (RNTCP): lessons learnt & challenges ahead. Indian J Med Res (2013) 1.21
Prevalence of dental caries and treatment needs amongst the school children of three educational zones of urban Delhi, India. Indian J Dent Res (2011) 1.20
Feasibility and effectiveness of provider initiated HIV testing and counseling of TB suspects in Vizianagaram district, South India. PLoS One (2012) 1.20
Cancer-preventing attributes of probiotics: an update. Int J Food Sci Nutr (2010) 1.20
State and socio-demographic group variation in out-of-pocket expenditure, borrowings and Janani Suraksha Yojana (JSY) programme use for birth deliveries in India. BMC Public Health (2012) 1.20
TXNIP links innate host defense mechanisms to oxidative stress and inflammation in retinal Muller glia under chronic hyperglycemia: implications for diabetic retinopathy. Exp Diabetes Res (2012) 1.19
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Estrogen effects on cognition and hippocampal transcription in middle-aged mice. Neurobiol Aging (2007) 1.19
Hydrogen sulfide mitigates transition from compensatory hypertrophy to heart failure. J Appl Physiol (1985) (2011) 1.18
Angiotensinogen gene polymorphism at -217 affects basal promoter activity and is associated with hypertension in African-Americans. J Biol Chem (2002) 1.18
Magnetic switching of ferroelectric domains at room temperature in multiferroic PZTFT. Nat Commun (2013) 1.18
Mirizzi syndrome and gallbladder cancer. J Hepatobiliary Pancreat Surg (2006) 1.18
Chemical profile, antifungal, antiaflatoxigenic and antioxidant activity of Citrus maxima Burm. and Citrus sinensis (L.) Osbeck essential oils and their cyclic monoterpene, DL-limonene. Food Chem Toxicol (2010) 1.17
Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res (2012) 1.17
Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia. Am J Physiol Heart Circ Physiol (2008) 1.17
Mechanisms of cardiovascular remodeling in hyperhomocysteinemia. Antioxid Redox Signal (2011) 1.16
Hydrogen sulfide regulates homocysteine-mediated glomerulosclerosis. Am J Nephrol (2010) 1.16
Case report: Endotracheal tube malposition in a patient with a tracheal bronchus. Can J Anaesth (2006) 1.16
Signaling mechanisms in mammalian myoblast fusion. Sci Signal (2013) 1.15
Flagellin stimulates protective lung mucosal immunity: role of cathelicidin-related antimicrobial peptide. J Immunol (2010) 1.15
IL-10 regulation by HIV-Tat in primary human monocytic cells: involvement of calmodulin/calmodulin-dependent protein kinase-activated p38 MAPK and Sp-1 and CREB-1 transcription factors. J Immunol (2007) 1.15
Role of matrix metalloproteinase-9 in endothelial apoptosis in chronic heart failure in mice. J Appl Physiol (1985) (2005) 1.14
Mitochondrial mechanism of microvascular endothelial cells apoptosis in hyperhomocysteinemia. J Cell Biochem (2006) 1.14
The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded. Cardiovasc Diabetol (2005) 1.14
Apoptosis in the left ventricle of chronic volume overload causes endocardial endothelial dysfunction in rats. Am J Physiol Heart Circ Physiol (2002) 1.14
TNF-like weak inducer of apoptosis (TWEAK) activates proinflammatory signaling pathways and gene expression through the activation of TGF-beta-activated kinase 1. J Immunol (2009) 1.14
Homocysteine-mediated activation and mitochondrial translocation of calpain regulates MMP-9 in MVEC. Am J Physiol Heart Circ Physiol (2006) 1.13
Genetic ablation of TWEAK augments regeneration and post-injury growth of skeletal muscle in mice. Am J Pathol (2010) 1.13